Skip to main content

Advertisement

SpringerLink
Log in

Management of the New Patient with CML in Chronic Phase

  • Chronic Leukemias (J Goldman, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted • Of importance •• Of major importance

  1. • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9. First report on the randomised trial comparing imatinib with nilotinib.

    Article  PubMed  CAS  Google Scholar 

  2. • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70. First report on the randomised trial comparing imatinib with dasatinib.

    Article  PubMed  CAS  Google Scholar 

  3. Lin F, Chase A, Bungey J, Goldman JM, Cross NC. Correlation between the proportion of Philadelphia chromosome- positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosomes. Cancer. 1995;13:110–4.

    CAS  Google Scholar 

  4. Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006;355:2408–17.

    Article  PubMed  CAS  Google Scholar 

  5. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–44.

    Article  PubMed  CAS  Google Scholar 

  6. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol. 2010;47:312–8.

    Article  PubMed  CAS  Google Scholar 

  7. • Marin D, Ibrahim AR, Lucas CM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–8. Evidence that the best way to identify those patients who may not fare weel on imatinib is a single measurament of the BCR-ABL transcript level done at 3 months.

    Article  PubMed  CAS  Google Scholar 

  8. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123–9.

    Article  PubMed  CAS  Google Scholar 

  9. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841–51.

    Article  PubMed  CAS  Google Scholar 

  10. Aichberger KJ, Herndlhofer S, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2012;86:533–9.

    Article  Google Scholar 

  11. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745–7.

    Article  PubMed  Google Scholar 

  12. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.

    Article  PubMed  CAS  Google Scholar 

  13. Kim D, Goh HG, Kim SH, Cho BS, Kim DW. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int J Hematol. 2011;94:361–71.

    Article  PubMed  CAS  Google Scholar 

  14. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377–86.

    Article  PubMed  CAS  Google Scholar 

  15. Montani D, Bergot E, G++nther S et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation 2012; Pre-published online ahead of print.

  16. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.

    Article  PubMed  CAS  Google Scholar 

  17. Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.

    Article  PubMed  CAS  Google Scholar 

  18. Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011;29:4260–5.

    Article  PubMed  CAS  Google Scholar 

  19. Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukaemia treated with first line dasatinib. Blood. 2012;102:291–4.

    Article  Google Scholar 

  20. Cortes JE, Jones D, O’Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392–7.

    Article  PubMed  CAS  Google Scholar 

  21. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28:398–404.

    Article  PubMed  CAS  Google Scholar 

  22. •• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. First report on discontinuing imatinib in patients who had achieved CMR.

    Article  PubMed  CAS  Google Scholar 

  23. Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX. Curing chronic myeloid leukemia. Curr Hematol Malignancy Rep. 2012;7:103–8.

    Article  Google Scholar 

Download references

Acknowledgments

I thank Prof. John Goldman for critical review of this manuscript.

Disclosure

Research support by Novartis and BMS.

Author information

Authors and Affiliations

  1. Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK

    David Marin

Authors
  1. David Marin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Marin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marin, D. Management of the New Patient with CML in Chronic Phase. Curr Hematol Malig Rep 8, 37–42 (2013). https://doi.org/10.1007/s11899-012-0151-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-012-0151-0

Keywords

Search

Navigation